Want to see TSE:BBM full AI Analyst Report?
Top Page
Blueberries Medical
(BBM)
Select Model
Select Model
Rating:47Neutral
Price Target:
C$0.02
▼(-25.00% Downside)
Action:Reiterated
Date:09/27/26
The score is held down primarily by weak financial performance—declining TTM revenue, extremely large operating/net losses, and ongoing negative free cash flow—alongside balance-sheet strain from significant equity erosion. Technicals are more neutral (price near key averages; RSI near 52), but they are not strong enough to offset the fundamental risk. Valuation is difficult to support with a negative P/E and no dividend yield.
Positive Factors
Gross Margin Improvement
The substantial improvement in gross margin indicates better economics on the products or services already being sold. If maintained, this can provide greater contribution toward operating expenses and support eventual breakeven, although current losses remain very large.
Negative Factors
Revenue Decline
Declining and uneven revenue makes it harder to spread fixed operating costs across a growing sales base. Continued top-line weakness could limit investment capacity, weaken market traction, and delay the operating scale needed to convert improving gross margin into profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Gross Margin Improvement
The substantial improvement in gross margin indicates better economics on the products or services already being sold. If maintained, this can provide greater contribution toward operating expenses and support eventual breakeven, although current losses remain very large.
Read all positive factors
Blueberries Medical (BBM) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$7.43M
Dividend YieldN/A
Average Volume (3M)33.92K
Price to Earnings (P/E)―
Beta (1Y)-2.04
Revenue Growth-36.67%
EPS Growth40.54%
CountryCA
Employees51
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding495,090,100
10 Day Avg. Volume29,904
30 Day Avg. Volume33,918
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)14.73
Price to Sales (P/S)15.15
P/FCF Ratio-3.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Blueberries Medical Business Overview & Revenue Model
Company Description
Headquartered in Bogotá, Colombia, Blueberries Medical Corp. operates within the medicinal cannabis industry. The company's activities encompass the entire process, from cultivating and developing to producing and supplying medical-grade cannabis ...
Blueberries Medical Financial Statement Overview
Summary
Income Statement
23
Negative
Balance Sheet
46
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 278.21K | 312.29K | 471.41K | 288.27K | 235.45K | 138.75K |
| Gross Profit | 102.20K | 49.50K | 164.52K | 84.22K | -17.72K | -245.45K |
| EBITDA | -695.46K | -1.28M | -1.04M | -1.22M | -811.47K | -4.05M |
| Net Income | -1.07M | -1.67M | -1.15M | -1.64M | -1.47M | -5.15M |
Balance Sheet | ||||||
| Total Assets | 670.10K | 679.62K | 1.38M | 2.42M | 3.35M | 3.59M |
| Cash, Cash Equivalents and Short-Term Investments | 14.77K | 26.39K | 66.08K | 818.16K | 1.41M | 1.34M |
| Total Debt | 8.28K | 137.88K | 11.44K | 12.80K | 1.34M | 1.44M |
| Total Liabilities | 641.44K | 358.45K | 545.61K | 470.72K | 1.89M | 2.16M |
| Stockholders Equity | 28.66K | 321.17K | 834.81K | 1.95M | 1.47M | 1.43M |
Cash Flow | ||||||
| Free Cash Flow | -607.78K | -1.24M | -796.85K | -1.35M | -1.47M | -1.73M |
| Operating Cash Flow | -607.78K | -1.24M | -796.85K | -1.33M | -1.47M | -1.68M |
| Investing Cash Flow | 0.00 | 0.00 | 9.00K | 382.92K | 101.94K | -48.77K |
| Financing Cash Flow | 394.76K | 1.18M | -1.95K | 539.10K | 1.35M | 2.77M |
Blueberries Medical Technical Analysis
Positive
0.02
Price Trends
0.01
Positive
0.01
Positive
0.01
Positive
Market Momentum
>-0.01
Positive
51.94
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BBM, the sentiment is Positive. The current price of 0.02 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.01, and above the 200-day MA of 0.01, indicating a bullish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 51.94 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BBM.
Blueberries Medical Peers Comparison
UnderperformOutperform
Sector (51)
TSE:BBM
Blueberries Medical
0.02
0.00
0.00%
TSE:BAMM
Body & Mind
0.03
0.00
0.00%
TSE:CDVA
CordovaCann
0.03
-0.03
-54.55%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.